CETP Gets Another Go: NewAmsterdam Phase III Trial Shows Safety And Efficacy

 
• By Jessica Merrill
Obicetrapib showed a benefit on LDL-C reduction in patients with HeFH • Source: Shutterstock

More from Cardiovascular

More from Therapeutic Category